The RA-MAP Consortium: a working model for academia–industry collaboration

The RA Map Consortium; Andrew P. Cope; Michael R. Barnes; Alexanda Belson; Michael Blinks; Sarah Brockbank; Francisco Bonachela-Capdevila; Claudia Carini; Benjamin A. Fischer; Carl S. Goodyear; Paul Emery; Michael R. Ehrenstein; Neil Gozzard; Ray Harris; Sally Hollis; Sarah Keidel; Marc Levesque; Catharina Lindholm; Michael F. McDermott; Iain B. McInnes; Christopher M. Mela; Gerry Parker; Simon Read; Ayako Wakatsuki Pedersen; Frederique Ponchel; Duncan Porter; Ravi Rao; Anthony Rowe; Peter Schulze-Knappe; Matthew A. Sleeman; Deborah Symmons; Peter C. Taylor; Brian Tom; Wayne Tsuji; Denny Verbeeck; John D. Isaacs

doi:10.1038/nrrheum.2017.200

The RA-MAP Consortium: a working model for academia–industry collaboration

The RA Map Consortium, Andrew P. Cope, Michael R. Barnes, Alexanda Belson, Michael Blinks, Sarah Brockbank, Francisco Bonachela-Capdevila, Claudia Carini, Benjamin A. Fischer, Carl S. Goodyear, Paul Emery, Michael R. Ehrenstein, Neil Gozzard, Ray Harris, Sally Hollis, Sarah Keidel, Marc Levesque, Catharina Lindholm, Michael F. McDermott, Iain B. McInnesChristopher M. Mela, Gerry Parker, Simon Read, Ayako Wakatsuki Pedersen, Frederique Ponchel, Duncan Porter, Ravi Rao, Anthony Rowe, Peter Schulze-Knappe, Matthew A. Sleeman, Deborah Symmons, Peter C. Taylor, Brian Tom, Wayne Tsuji, Denny Verbeeck, John D. Isaacs

Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of 'big data'. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.

Original language	English
Pages (from-to)	53-60
Number of pages	8
Journal	Nature reviews rheumatology
Volume	14
Early online date	7 Dec 2017
DOIs	https://doi.org/10.1038/nrrheum.2017.200
Publication status	Published - 1 Jan 2018

Access to Document

10.1038/nrrheum.2017.200Licence: Other

Cite this

The RA Map Consortium, Cope, A. P., Barnes, M. R., Belson, A., Blinks, M., Brockbank, S., Bonachela-Capdevila, F., Carini, C., Fischer, B. A., Goodyear, C. S., Emery, P., Ehrenstein, M. R., Gozzard, N., Harris, R., Hollis, S., Keidel, S., Levesque, M., Lindholm, C., McDermott, M. F., ... Isaacs, J. D. (2018). The RA-MAP Consortium: a working model for academia–industry collaboration. Nature reviews rheumatology, 14, 53-60. https://doi.org/10.1038/nrrheum.2017.200

@article{5452984ddbdf460180610bb653bf2bbb,

title = "The RA-MAP Consortium: a working model for academia–industry collaboration",

abstract = "Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of 'big data'. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.",

author = "Adwoa Parker and {The RA Map Consortium} and Cope, {Andrew P.} and Barnes, {Michael R.} and Alexanda Belson and Michael Blinks and Sarah Brockbank and Francisco Bonachela-Capdevila and Claudia Carini and Fischer, {Benjamin A.} and Goodyear, {Carl S.} and Paul Emery and Ehrenstein, {Michael R.} and Neil Gozzard and Ray Harris and Sally Hollis and Sarah Keidel and Marc Levesque and Catharina Lindholm and McDermott, {Michael F.} and McInnes, {Iain B.} and Mela, {Christopher M.} and Gerry Parker and Simon Read and {Wakatsuki Pedersen}, Ayako and Frederique Ponchel and Duncan Porter and Ravi Rao and Anthony Rowe and Peter Schulze-Knappe and Sleeman, {Matthew A.} and Deborah Symmons and Taylor, {Peter C.} and Brian Tom and Wayne Tsuji and Denny Verbeeck and Isaacs, {John D.}",

year = "2018",

month = jan,

day = "1",

doi = "10.1038/nrrheum.2017.200",

language = "English",

volume = "14",

pages = "53--60",

journal = "Nature reviews rheumatology",

issn = "1759-4790",

publisher = "Nature Publishing Group",

}

The RA Map Consortium, Cope, AP, Barnes, MR, Belson, A, Blinks, M, Brockbank, S, Bonachela-Capdevila, F, Carini, C, Fischer, BA, Goodyear, CS, Emery, P, Ehrenstein, MR, Gozzard, N, Harris, R, Hollis, S, Keidel, S, Levesque, M, Lindholm, C, McDermott, MF, McInnes, IB, Mela, CM, Parker, G, Read, S, Wakatsuki Pedersen, A, Ponchel, F, Porter, D, Rao, R, Rowe, A, Schulze-Knappe, P, Sleeman, MA, Symmons, D, Taylor, PC, Tom, B, Tsuji, W, Verbeeck, D & Isaacs, JD 2018, 'The RA-MAP Consortium: a working model for academia–industry collaboration', Nature reviews rheumatology, vol. 14, pp. 53-60. https://doi.org/10.1038/nrrheum.2017.200

TY - JOUR

T1 - The RA-MAP Consortium

T2 - a working model for academia–industry collaboration

AU - Parker, Adwoa

AU - The RA Map Consortium

AU - Cope, Andrew P.

AU - Barnes, Michael R.

AU - Belson, Alexanda

AU - Blinks, Michael

AU - Brockbank, Sarah

AU - Bonachela-Capdevila, Francisco

AU - Carini, Claudia

AU - Fischer, Benjamin A.

AU - Goodyear, Carl S.

AU - Emery, Paul

AU - Ehrenstein, Michael R.

AU - Gozzard, Neil

AU - Harris, Ray

AU - Hollis, Sally

AU - Keidel, Sarah

AU - Levesque, Marc

AU - Lindholm, Catharina

AU - McDermott, Michael F.

AU - McInnes, Iain B.

AU - Mela, Christopher M.

AU - Parker, Gerry

AU - Read, Simon

AU - Wakatsuki Pedersen, Ayako

AU - Ponchel, Frederique

AU - Porter, Duncan

AU - Rao, Ravi

AU - Rowe, Anthony

AU - Schulze-Knappe, Peter

AU - Sleeman, Matthew A.

AU - Symmons, Deborah

AU - Taylor, Peter C.

AU - Tom, Brian

AU - Tsuji, Wayne

AU - Verbeeck, Denny

AU - Isaacs, John D.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of 'big data'. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.

AB - Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of 'big data'. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.

U2 - 10.1038/nrrheum.2017.200

DO - 10.1038/nrrheum.2017.200

M3 - Article

SN - 1759-4790

VL - 14

SP - 53

EP - 60

JO - Nature reviews rheumatology

JF - Nature reviews rheumatology

ER -